Clinical trials: Delivery Delayed
X-Linked Myotubular Myopathy
A Study of AT132 in Young Children With X-Linked Myotubular Myopathy (XLMTM)
X-linked myotubular myopathy (XLMTM) is a rare and serious condition present at birth where the muscles do not work properly. There are currently no therapies for this serious condition.
- Trial name
- ASPIRO (NCT03199469)
- Testing
- Resamirigene bilparvovec
- Where
- 6 sites in United States, Canada and 2 more
- Volunteers
- 27 people
- Sponsor
- Astellas Gene Therapies
Crohn's Disease
Efficacy Study of Targeted, Local Delivery of Drugs to Treat Crohn's Disease
The study is being undertaken to evaluate whether delayed-release medications, designed to begin to open in the lower intestinal tract, the main site of Crohn's Disease, are more effective than standard systemically delivered…
- Trial name
- NCT00287170
- Testing
- Delayed Release 6MP or Calcitriol vs. Purinethol
- Where
- Israel
- Volunteers
- 15 people
- Sponsor
- Teva GTC
HIV-1 Infection, Receipt of Cal-1 Modified Hematopoietic Cellular Products
Long Term Follow up for the Detection of Delayed Adverse Events in Cal-1 Recipients
Long term safety follow-up of Cal-1 recipients
- Trial name
- NCT02390297
- Testing
- Blood tests
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Calimmune, Inc.
Preterm Labor
A Phase 2 Study of OBE001 Versus Placebo in the Delay of Preterm Birth
The primary objective of this study is to assess the efficacy of a single dose of OBE001, an oral oxytocin antagonist, given for up to 7 days to delay preterm birth by 7 days compared to placebo.
- Trial name
- TERM (NCT02326142)
- Testing
- OBE001
- Where
- 23 sites in Belgium, Germany and 4 more
- Volunteers
- 10 people
- Sponsor
- ObsEva SA
Crohn's Disease
Multicenter Clinical Efficacy and Safety Study of Delayed Release 6MP in Crohn's Disease
The study is designed to evaluate the clinical efficacy and safety of daily treatment for 12 weeks of oral administration of a delayed release, locally delivered 6MP (mercaptopurine) drug (80 mg), as compared to standard…
- Trial name
- NCT01094613
- Testing
- Delayed Release 6 mercaptopurine, 6 Mercaptopurine
- Where
- 11 sites in Israel
- Volunteers
- 70 people
- Sponsor
- Teva GTC
Crigler-Najjar Syndrome
Gene Transfer Clinical Study in Crigler-Najjar Syndrome
This is a Phase 1/2, multinational, open-label, ascending-dose, delayed-treatment concurrent control clinical study to evaluate the safety and preliminary efficacy of AT342 in subjects with Crigler-Najjar aged ≥1 year.
- Trial name
- VALENS (NCT03223194)
- Testing
- AT342
- Where
- 4 sites in United States, Israel and 1 more
- Volunteers
- 1 people
- Sponsor
- Audentes Therapeutics
Cardiovascular Diseases, Arrhythmias, Cardiac
Intracardiac Echocardiography Catheter Supply-Chain Reliability and Clinical Access Study
The ICE-ACCESS study is a prospective observational study designed to evaluate how procurement reliability, distribution restrictions, supply-chain interruptions, and device availability affect access to intracardiac…
- Conditions
- Cardiovascular Diseases, Arrhythmias, Cardiac, Atrial Fibrillation
- Trial name
- ICE-ACCESS (NCT07788040)
- Testing
- Intracardiac Echocardiography Catheter
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Truway Health, Inc.
Crohns Disease
Pilot Comparative Bioavailability Study of 6Mercaptopurine (Delayed Release vs. Purinethol) in Crohns Disease Patients
The study is being conducted to evaluate the pharmacokinetic parameters (Cmax, Tmax and AUC) of the new delayed release, lowered dose, 40 mg 6MP test formulation as compared to standard 6MP (100 mg Purinethol) in 12 patients with…
- Trial name
- NCT00774982
- Testing
- Delayed Release 6 mercaptopurine, 6 Mercaptopurine
- Where
- Israel
- Volunteers
- 12 people
- Sponsor
- Teva GTC
Healthy Volunteers
A Study to Investigate the Use of Delayed Release Tablets for Colonic Delivery of Brilacidin in Healthy Volunteers
This is a single-centre, blinded, randomized, placebo controlled, dose escalation study. Up to 9 healthy male volunteers will participate in the study.
- Trial name
- NCT04240223
- Testing
- Brilacidin, 4Mq 99mTc-DTPA
- Where
- United Kingdom
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Innovation Pharmaceuticals, Inc.
Clostridium Difficile Infection (CDI)
Study of Metronidazole Delayed-Release Capsules in Comparison With Immediate-Release Tablets (Flagyl) for Safety and Pharmacokinetics
Clostridium difficile Infection (CDI) also referred to as Clostridium difficile associated diarrhea (CDAD) is an infectious disease that is commonly associated with taking broad-spectrum antimicrobials and certain cancer…
- Trial name
- NCT07251127
- Testing
- Delayed-release metronidazole, Immediate-release metronidazole
- Where
- India
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Gateway Pharmaceutical LLC
Contraception
Effect of Norgestrel 75 mcg on Cervical Mucus and Ovarian Activity During Perfect Use, After One Delayed Intake and After a Missed Pill
Norgestrel 75 mcg is a progestin-only pill (POP), which is a kind of oral birth control pill. To be effective in preventing pregnancy, this kind of birth control pill is supposed to be taken every day at the same time, without…
- Trial name
- NCT03585712
- Testing
- Norgestrel 0.075 mg
- Where
- 2 sites in United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- HRA Pharma
Endometrial Receptivity
The ERA Test as a Diagnostic Guide for Personalized Embryo Transfer
This project seeks to demonstrate the clinical value of the personalised diagnosis of the endometrial factor in infertility.
- Trial name
- ERA RCT (NCT01954758)
- Testing
- personalized Embryo Transfer (pET), Frozen Embryo Transfer (FET), Fresh Embryo Transfer (ET)
- Where
- 16 sites in Belgium, Brazil and 5 more
- Volunteers
- 569 people
- Sponsor
- Igenomix
Hemophilia B
LTFU for Gene Transfer Subjects With Hemophilia B
Several subjects enrolled in a multi-site, gene transfer clinical study to evaluate the intrahepatic administration of AAV2-hFIX16 vector for the treatment of severe hemophilia B between 2001 and 2009.
- Trial name
- NCT00515710
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Spark Therapeutics, Inc.
Crohn's Disease
Open Label Extension Study to Protocol C2/13/DR-6MP-02
The open label extension study (Protocol C2/13/DR-6MP-02 EXT) is designed to evaluate the clinical efficacy and safety of 80 mg DR-6MP test formulation for an additional 12 weeks in subjects who already completed 12 weeks of…
- Trial name
- OLE (NCT01433432)
- Testing
- 80 mg DR-6MP
- Sponsor
- Teva GTC